NCT00143377View on ClinicalTrials.gov

Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB

PHASE4CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

October 31, 2005

Conditions
Urinary Incontinence
Interventions
DRUG

tolterodine SR, overactive bladder

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00143377 - Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB | Biotech Hunter | Biotech Hunter